Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether patients who are likely to fail R-CHOP, as
predicted by a mid-treatment PET scan, can have an improved outcome if switched to a standard
salvage regimen R-ICE (rituximab, ifosfamide, carboplatin, etoposide).
Patients who have a negative PET scan after 4 cycles of R-CHOP have an excellent prognosis
(>85% chance of cure) and should complete treatment with 6 cycles of standard R-CHOP.
Patients who have a positive PET scan after 4 cycles of R-CHOP have a very poor prognosis
(~10% chance of cure) and may have an improved outcome if switched to a non-cross resistant
chemotherapy combination R-ICE.